Discounted Cash Flow (DCF) Analysis Unlevered

La Jolla Pharmaceutical Company (LJPC)

$6.22

0.00 (-%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 6.22 | undervalue

Operating Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
Revenue (%)
EBITDA ----------
EBITDA (%)
EBIT ----------
EBIT (%)
Depreciation ----------
Depreciation (%)

Balance Sheet Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Total Cash ----------
Total Cash (%)
Account Receivables ----------
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable ----------
Accounts Payable (%)
Capital Expenditure ----------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 6.22
Beta 2.408
Diluted Shares Outstanding 34.18
Cost of Debt
Tax Rate 0.25
After-tax Cost of Debt 394.71%
Risk-Free Rate
Market Risk Premium
Cost of Equity 14.883
Total Debt 2.64
Total Equity 212.59
Total Capital 215.24
Debt Weighting 1.23
Equity Weighting 98.77
Wacc

Build Up Free Cash

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
EBITDA ----------
EBIT ----------
Tax Rate 0.00%0.00%0.00%0.00%0.25%0.05%0.05%0.05%0.05%0.05%
EBIAT ----------
Depreciation ----------
Accounts Receivable ----------
Inventories ----------
Accounts Payable ----------
Capital Expenditure -9.19-2.34-0.70--0.01-----
UFCF ----------
WACC
PV UFCF -----
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 19.55
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -44.02
Equity Value -
Shares Outstanding 34.18
Equity Value Per Share -